Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novartis

Stock Market Rally Breaks Higher; Tesla, Netflix, Snap, United Airlines Key Earnings: Weekly Review

The stock market rally gained steam, breaking above key levels. Tesla soared on earnings, but the Fed and a big week of results loom.

Investors Business Daily

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

How Novartis' Laggard Business Was Its Second-Quarter Saving Grace

Swiss drugmaker Novartis delivered a mixed second-quarter report Tuesday, but Novartis stock popped on the company's bullish outlook.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread

Aurinia Pharmaceuticals hired a trio of executives in a move that suggests it's nowhere near a buyout — and AUPH stock plummeted Friday.

Investors Business Daily

Former Tioxide site relaunched as a major industrial location by ABP as Rolls-Royce shortlisting secured

Sprawling Humber bank location opened up as part of major land release by port operator

Birmingham Post

India’s patent law safeguards under fire

The new recommendation reduces the period within which patent applications can be challenged to six months

The Hindu

Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug

Celldex took aim at Roche and Novartis' blockbuster hives drug on Friday with a small study that showed promise — but CLDX stock tumbled.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study

Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Benzinga

Novartis Resumes Production, Delivery Of Radioligand Therapy Medicines

Novartis AG (NYSE:NVS) said that in early June, it restarted radioligand therapy (RLT) production at its sites in Ivrea, Italy, and Millburn, New Jersey. It also resumed delivering doses to patients in a phased approach, ahead of the expected six-week timeframe. The company has remediated the issues that led to a temporary, voluntary suspension…

Benzinga

With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors

Key Takeaways: Laekna is seeking a Hong Kong IPO to raise funds to accelerate the commercialize two core products licensed from Novartis The company currently is not generating any sale, with most of its products in early stages of development By Tina Yip

Benzinga

Novartis Announces $250M In R&D Funding For Neglected Tropical Diseases, Malaria

Novartis AG (NYSE:NVS) is pledging $250 million into R&D for new treatments of neglected tropical diseases (NTD) and malaria, with an aim to eliminate these diseases. "Over the past decade, great progress has been made against NTDs, but there is still a lot more work to be done," CEO Vas Narasimhan said. Novartis…

Benzinga

FDA Gives Approval For Novartis' Tafinlar + Mekinist Broadens BRAF/MEK Cancer Combo Use

The FDA granted accelerated approval to Novartis AG's (NYSE:NVS) pairing of Tafinlar and Mekinist for any advanced solid tumors with the BRAF V600E mutation. The patient must have progressed following prior therapy and have no alternative treatment options. The combo is already approved for BRAF mutated non-small cell lung cancer, melanoma, and thyroid cancer.…

Benzinga

Why Precision BioSciences Shares Are Surging Today

Precision BioSciences Inc (NASDAQ:DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE:NVS) Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a "safe harbor" location in the genome as a potential one-time…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Hindu

Explained | The Indian patent regime and its clash with the U.S. norms

The U.S. Trade Representative highlighted IP challenges in India in its annual Special 301 report released last month

Bangkok Post

Firms rejig to survive in lean times

Businesses adopted cost reduction, increased productivity, and emphasised environmental standards to cope with the pandemic and global challenges stemming from the Russia-Ukraine war, panellists told the Forbes Thailand 2022 Forum on Monday.

Reuters

Novartis drug combo shows promise in childhood brain cancer

An oral drug combination by Swiss pharmaceuticals company Novartis showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.

Birmingham Post

Work on environmental and economic Novartis 'leaving gift' legacy begins

Wetland habitat to be created to enable future inward investment and economic development at pace

Get all your
news in one place.

100’s of premium titles.
One news app.

The Hindu

KTR hardsells Telangana at Davos

Meets top honchos of tech and pharma companies

Birmingham Post

Buyer of Novartis Grimsby outlines what could be next for 'world-class' pharmaceutical complex

International Process Plants has taken it on under new subsidiary Humber Industrials Ltd - eyeing onshoring of production as a possibility

Asharq Al-Awsat

Cancer Coalition Aims to Boost Access to Medicines in Poorer Countries

Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organizations in an alliance aimed at getting more oncology medications to poorer countries. Currently, fewer than 50% of the cancer drugs on the World Health Organization's (WHO) essential medicines list are available in low and middle income countries,…

Birmingham Post

All Novartis jobs to go as land and process plant sale agreed with international industrial dealer

Slim hopes of a going concern sale of Grimsby site appear to have been dashed - with remaining 212 employees now facing redundancy

Benzinga

5 Value Stocks In The Healthcare Sector

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Investors Business Daily

Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis

Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.

Benzinga

5 Value Stocks To Watch In The Healthcare Sector

What Defines a Value Stock?

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.